A thrombin receptor (TR) demonstrating a unique activation mechanism has recently been isolated from a megakaryocytic (Dami) cell line. To further study determinants of peptide ligand-mediated activation phenomenon, we have isolated, cloned, and stably expressed the identical receptor from a human umbilical vein endothelial cell (HUVEC) library. Chinese hamster ovary (CHO) cells expressing a functional TR (CHO-TR), platelets, and HUVECs were then used to specifically characterize a-thrombin-and peptide ligand-induced activation responses using two different antibodies: anti-TR"52 directed against a 20-amino acid peptide spanning the thrombin cleavage site, and anti-TR'" generated against the NH2-terminal 160 amino acids of the TR expressed as a chimeric protein in Escherichia coli. Activation-dependent responses to both athrombin (10 nM) and peptide ligand (20 MM) were studied using fura 2-loaded cells and microspectrofluorimetry. 
Introduction a-Thrombin initiates a molecular dialogue between platelets, the endothelium, and other coagulation proteins that is funda-mental to the ultimate control of the hemostatic response. In addition to its well-defined role in coagulation (1) , a-thrombin is among the most potent of physiological stimuli for platelet activation (2) . Interaction of a-thrombin with the endothelium results in the release of von Willebrand factor, modulation of fibrinolytic activity, and endothelial cell retraction, resulting in selective permeability of the vascular wall (3) . A receptor for a-thrombin has recently been isolated by expression cloning in Xenopus oocytes using mRNA from the Dami megakaryocytic cell line (4) . This receptor is structurally similar to other members of the seven-transmembrane receptor family (5) , elicits elevation of cytosolic calcium in response to physiological doses of a-thrombin, and fails to respond to D-phenylalanyl-prolyl-arginine chloromethyl ketone (PPACK)-and hirudin-treated thrombin. A putative thrombin cleavage site has been identified, and a 14-amino acid peptide mimicking the new NH2 terminus has been shown to act as a potent agonist for activation of platelets (4, 6) , endothelial cells (7), and other cells (8, 9) expressing similar thrombin receptors (TRs).' In platelets, both the peptide and proteolytically active thrombin similarly lead to phospholipase C and 3-phosphorylated phosphoinositide (3,4-bisphosphate and 3,4,5-trisphosphate) accumulation (10) and both inhibit adenylate cyclase activity (1 1).
Smaller peptides derived from the new NH2 terminus may equally or more potently activate the receptor (12) .
We have initiated studies designed to address structural features ofpeptide ligand-mediated thrombin receptor cell activation. We have isolated, cloned, and stably expressed a TR from a human umbilical vein endothelial cell (HUVEC) library and demonstrated that it is structurally identical to its platelet-derived counterpart. Comparative activation-dependent responses to both a-thrombin and peptide ligand were subsequently evaluated in stably transfected Chinese hamster ovary (CHO) cells (CHO-TR), cultured endothelial cells, and platelets, using two antibodies directed against different regions of the receptor. One antibody (anti-TR"lW), directed (13) . A functionally inactive 14-amino acid peptide spanning residues 42-55 (TIC2, FSLLRNPNDKYEPF) in which the first two residues were reversed in position was synthesized as a control. A 20-amino acid peptide encompassing the thrombin cleavage site with an added NH2-terminal cysteine (TR34-52, Ac-CTNATLDPRSFLLRNPNDKY-NH2) was synthesized for use as an immunogen (see below). All peptides were synthesized using t-boc chemistry on an automated synthesizer (Model 430A; Applied Biosystems, Inc., Foster City, CA) as COOH-terminal amides and with acetylated NH2 termini. The TR 4-52 peptide was treated with base to reverse any N --0 shift of the serine and threonine residues and purified by reverse-phase HPLC. Restriction enzymes were purchased from Stratagene, Inc. (La Jolla, CA), Isolation and cDNA cloning of endothelial cell-derived TR. The construction of both random-primed and oligo(dT)-primed HUVEC cDNA libraries cloned into the expression vector Xgt-11 has been previously described (14). cDNA inserts were directly labeled in 1% low melting agarose by random hexamer priming (15) and used for further screening by standard techniques (16) . Sequence analysis was completed in Ml 3mp18 using dideoxy chain termination (17) and T7 DNA polymerase (Sequenase; U.S. Biochemical Corp., Cleveland, OH). Oligonucleotides were synthesized on an single channel synthesizer (Applied Biosystems, Inc.). The polymerase chain reaction (PCR) was completed using 35 rounds on a thermocycler (Coy Laboratory Products Inc., Ann Arbor, MI) as previously described (18) , and products were analyzed by electrophoresis in a 1% ethidium-stained agarose gel. The amplifications performed directly from the HUVEC library were completed after boiling the phage template DNA for 3 min. Reverse transcription was completed by incubating 3 Ag ofendothelial cell RNA (19) with 1 Mg ofa 14-mer oligo(dT) primer at 41°C for 1 h using avian myeloblastosis virus reverse transcriptase (Seikagaku America Inc., Rockville, MD). 10 ,l ofa 50-Ml sample was then used in the PCR as previously described (20) .
Production of recombinant protein and antibody generation. The PCR fragment containing flanking BamHI and EcoRI restriction sites was purified by agarose gel electrophoresis, double digested, and directionally cloned in-frame into the prokaryotic expression vector pGEX2T (Pharmacia LKB Biotechnology Inc., Piscataway, NJ), thereby generating a chimeric fusion protein consisting ofglutathione-S-transferase and a portion ofthe TR (TR'60). The plasmid was transformed into Escherichia coli host strain Y1090, and fusion proteins were produced in liquid culture by induction with 10 mM isopropyl-f-D-thiogalactopyranoside for 2 h at 37°C. After lysis in a Dounce homogenizer, the insoluble fraction containing the recombinant protein was solubilized in 6 M guanidine hydrochloride and 10 mM DTT for 60 min at 25°C, and then renatured by stepwise dialysis at 4°C against decreasing concentrations of guanidine and PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 1.4 mM KH2PO4 Monitoring of cytosolic calcium concentration. HUVECs were isolated from pooled primary cultures of human umbilical veins as previously described (18) and used in passages 2-5. Cells were grown on gelatin-coated plates in M199 supplemented with 10% fetal calf serum, 100 ,ug/ml endothelial cell growth factor (Collaborative Research, Bedford, MA), 100 Mg/ml porcine intestinal heparin, penicillin (100 U/ml), and streptomycin (100 ,ug/ml). Confluent cells (CHO and HUVECs) were propagated on glass coverslips and exposed to serum-free medium 18-24 h before functional evaluation. Cells were subsequently loaded with 2.5MM fura 2/AM for 60 min at 25°C, rinsed with PBS, incubated in Krebs-Henseleit-bicarbonate buffer supplemented with 5 mM Hepes (3), and placed in a Leiden temperature-controlled chamber (Medical Systems Corp., Greenvale, NY) for analysis. The chamber was mounted on the stage of an inverted microscope (Diaphot; Nikon Inc., Garden City, NY) equipped with quartz optics. Individual cells were optically isolated and alternately illuminated at wavelengths of 345 and 380 nm using a dual-excitation delta scan microspectrofluorimeter (Photon Technologies International, Trenton, NJ). Measurements of fluorescence intensity were performed at a rate of 20 points/s, and the ratio 345:380 was used to calculate [Ca2i], applying fura 2/calcium standards as previously described (24) .
Platelet cytosolic calcium transients were studied using gel-filtered platelets (GFP). Platelet-rich plasma (PRP) was prepared from blood anticoagulated with acid-citrate dextrose (ACD) (8.5 ml blood/1.5 ml ACD), supplemented with 0.1 vol of additional ACD, and centrifuged at 2,000 g for 8 min at 22°C. The platelet pellet was resuspended in a small volume ofHepes-buffered modified-Tyrodes buffer (HMBT: 138 mM NaCl, 2.7 mM KCI, 0.4 mM NaH2PO4, 12 mM NaHCO3, 0.2% bovine serum albumin, and 10mM Hepes, pH 7.4) supplemented with 0.1 ,uM PGE,, but containing no cations. Platelets were then loaded with 3 MM fura 2/AM for 60 min at 37°C, passed over a column of Sepharose 2B (Pharmacia LKB Biotechnology Inc.) and resuspended in HBMT supplemented with 1 mM CaCI2 to a final concentration of 1.5 X 108 platelets/ml.
[Ca2+]i transients were then evaluated in stirred platelets illuminated at 340 nm at 37°C by measuring fluorescence intensity at 500 nm with a spectrofluorimeter (The Perkin Elmer Corp., Norwalk, CT).
Immunocytochemistry andflow cytometric analysis. PRP prepared from healthy human donors and flow cytometric analysis were performed as previously described (25) . Platelets anticoagulated with 10 mM EDTA were pelleted, resuspended in Tris-saline-EDTA (TSE) buffer (0.1 M Tris, 0.15 M NaCl, 10 mM EDTA, pH 7.4), and gel filtered through Sepharose 2B equilibrated with TSE. GFP were then diluted in the same buffer to a final concentration of 3.5-4.0 x 108 platelets/ml. Transfected CHO cells were grown in suspension culture in CHO-S-SFM serum-free media before analysis. Approximately 1-2 A0 x 106 CHO cells or 400-id aliquots ofGFP were incubated with specific antibodies in TSE buffer for 20 min at 250C, washed three times in TSE, and then incubated with the second affinity-purified, FITC-conjugated goat anti-rabbit F(ab')2 antibody (Tago, Inc., Burlingame, CA) at a dilution of 1:100 for 20 min at 250C. Cells were then washed one time in the same buffer, and one half of the sample was analyzed on a FACStarO analyzer (Becton Dickinson & Co., Rutherford, NJ).
For immunocytochemical evaluation, endothelial cells were grown on gelatin-coated coverslips as described above. Cells were either stained live or fixed, the latter in 2% paraformaldehyde for 20 min at 250C. After fixation, cells were washed three times with PBS, incubated with 10% horse serum for 60 min, and then with anti-TR'-"' (450 ,gg/ml) or preimmune control (450 tg/ml) for 60 min at 250C. After three washes, cells were incubated with the FHTC-conjugated goat antirabbit IgG at a dilution of 1:200 for 60 min before examination. Cells were studied with a fluorescence microscope using a B-dichroic mirror (Diaphot; Nikon Inc.). Images were collected with a silicon intensifier camera (Hamamatsu Photonics Microcopy, Oak Brook, IL) and processed using Universal Imaging software (Media, PA). Vital staining of live endothelial cells was performed essentially as above, omitting the fixation step and substituting Krebs-Henseleit-bicarbonate buffer for PBS. Initial images were obtained after the completion of the staining; cells were then treated with 500 U/ml trypsin (Sigma Chemical Co.) for 4 min, followed by addition of 5,000 U/ml soybean trypsin inhibitor (Sigma Chemical Co.).
Platelet aggregation studies. For aggregation induced by a-thrombin, GFP was prepared as described above using the HBMT buffer, except that the buffer contained 2 mM MgCl2. For aggregation induced by the peptide ligand, PRP was prepared from blood anticoagulated with 0.01 vol of 40% trisodium citrate. Platelets were resuspended to a final concentration of -3 X 108/ml, and 0.45 ml was used for aggregation studies. Preliminary experiments demonstrated maximal inhibition of platelet aggregation, induced with 1 nM a-thrombin, by anti-TR1 52 IgG and F(ab')2 of 125 and 250 ig/ml, respectively (26) . Concentrations equal to or greater than these were then used in subsequent experiments. Similarly, since preincubation times of20 min were sufficient to achieve maximal inhibition, subsequent studies were completed with incubation times of 2 20 min.
Results
Isolation ofendothelial cell-derived TR. The primers used for PCR are outlined in Fig. 1 (27) Fig. 1 B. This sequence contains no additional initiator methionine sequences (ATG) and, combined with the previously identified 224 bp of 5' sequence, confirms the presence of a 5'-untranslated region of > 300 bp. The significance of such long regions has been previously discussed (27 (Fig. 2 B) . This latter response is qualitatively similar to that previously described in HEL cells, although the rate of full recovery is more rapid (8 ity purified from total bacterial lysates as outlined above, electroeluted, and used for the generation of a specific rabbit polyclonal antibody (anti-TR'l-).
Documentation that the antibody recognized normally expressed TR was confirmed using platelets, transfected CHO cells, and HUVECs. Platelets and transfected CHO cells expressing the TR were incubated with anti-TR'-" or preimmune IgG and studied by flow cytometric analysis. Specific binding to platelets and CHO-17 cells was evident (Fig. 3) ; no demonstrable binding was evident using IgG purified from preimmune rabbits. Likewise, endothelial cells were grown on coverslips, fixed, and stained with anti-TR'-". As shown in Fig. 4 , specific staining is observed with anti-TR'-" whereas no immunofluorescence is observed with preimmune control IgG, demonstrating that the TR is normally expressed on cul- (Fig. 7 B) and platelets (Fig. 8 B) at approximately similar concentrations of 225 gg/ml. In sharp contrast to results observed in CHO-17 cells, however, anti-TR'-" did not abrogate the response of HUVECs or platelets to 10 nM a-thrombin. Rather, both cell types displayed a delayed but sustained elevation in [Ca2+]i transients, evident despite increasing concentrations of the antibody (Figs. 7 A and 8 C) .
Platelet aggregation. Anti-TR3152 IgG dramatically inhibited platelet aggregation induced by low concentrations of athrombin (1 nM), although some shape change remained (Fig.  9 A) . Increasing the concentration of a-thrombin overcame the inhibition. Similar data were obtained with F(ab')2 fragments of anti-TR3452, with 50% inhibition of aggregation induced by 1 nM a-thrombin requiring between 63 and 125 ,ug/ml of the F(ab')2 (data not shown). Anti-TR3"52 IgG had no significant effect on platelet aggregation induced by limiting concentrations of peptide ligand (6.2 ttM) in citrated PRP at concentrations up to 500 Ag/ml, a concentration that was very effective in inhibiting a-thrombin-induced aggregation (Fig. 9 B) . Likewise, anti-TR 52 F(ab')2 failed to inhibit peptide ligand-induced platelet aggregation at concentrations up to 340 ,g/ml (data not shown). In contrast, inhibitory effects to anti-TR'-" F(ab')2 fragments were seen when platelets were activated by either a-thrombin or the peptide ligand. Platelet aggregation to a-thrombin was inhibited in a dose-dependent fashion, although some shape change remained (Fig. 10) . Similar inhibitory effects were seen using peptide ligand as agonist. No inhibitory effects were seen when platelets were activated by ADP, confirming the specificity of the antibody for aggregation by a-thrombin and the peptide ligand agonist (Fig. 10 ). 
Discussion
A model for the activation of this TR by a-thrombin has been postulated. Accordingly, thrombin cleaves its receptor's amino-terminal extension, thereby creating a tethered ligand that presumably activates the receptor by binding to an as yet unidentified downstream recognition site (4). Thrombin interacts with the TR at least in part through the receptor's acidic hirudin-like domain, which is located adjacent to the thrombin cleavage site (31, 32) . The importance of the hirudin-like domain is supported by mutagenesis studies involving this region of the receptor (32) and by the inhibitory effect of hirudin-like domain peptides that bind to thrombin, presumably through the latter's anion-binding exosite (31) . More recently, polyclonal (33) and monoclonal antibodies (34) directed against synthetic peptides from these regions ofthe receptor have been shown to inhibit thrombin-induced platelet activation. Anti-TR3"52 is directed against a somewhat different peptide from the thrombin cleavage site and similarly inhibits a-thrombininduced platelet activation and aggregation. Neither ofthe previously described antibodies nor anti-TR 52, however, inhibit platelet activation or aggregation induced by synthetic peptide ligands modeled on the new NH2 terminus produced by thrombin cleavage. To date little is known about the mechanism by which the tethered ligand mediates receptor activation and, in particular, the proposed site on the remainder of the receptor to which it binds. Anti-TR'-', directed against a recombinant protein containing the NH2-terminal extension of the TR, up to and including the second transmembrane domain, inhibited both a-thrombin-and peptide ligand-mediated receptor activation in a heterologous cell line expressing the functionally active TR, in endothelial cells, and platelets. Because the recognition sequence for this antibody spans both the thrombin cleavage site and the hirudin-like domain, its inhibitory effect on thrombin-mediated receptor activation is not unexpected and is consistent with functional data using previously developed antibodies (26, 33, 34) . Its ability to inhibit peptide ligand-induced
[Ca2+]i transients, however, was unanticipated. The antibody also dramatically inhibited peptide ligand-induced platelet aggregation, although some shape change persisted, perhaps because ofrelease ofsmall amounts ofcalcium below the sensitivity of the detection system. The ability of the antibody to inhibit peptide ligand-induced activation further suggests that a recognition sequence ultimately critical for receptor activation is contained within the portion of the receptor recognized by anti-TR'-'". Alternatively, the antibody is exerting its effect by inhibiting conformational constraints necessary for peptide li- prevent- ing the binding of the peptide to the receptor, this binding site must be contained within the antigenic determinants of the antibody (residues 1-160). Since anti-TR'-" is unlikely to react with the transmembrane domains (TMS I and II) or the first intracytoplasmic (IC I) loop, the site responsible for its effect on peptide ligand-induced activation is most likely in the NH2-terminal extension of the receptor (amino acid residues 1-99). Moreover, the peptide-binding site is most likely distal to the thrombin cleavage site (LDPR/S, amino acids 41-42), thereby suggesting that the crucial site for peptide ligand-induced receptor activation may be further localized to residues Ser42-Ser99. Previous studies demonstrated that a polyclonal antibody directed against a peptide encompassing amino acid residues Tyr52-Tyr69, representing the hirudin-like domain (33), did not affect peptide ligand-mediated activation, although inhibition to a-thrombin was evident. Moreover, previous mutagenesis studies involving the hirudin-like domain of the TR failed to demonstrate any effect on peptide ligand-mediated receptor activation (32) . Extrapolation from these data would further suggest that a sequence or sequences between amino acids Arg7O and Ser99 is involved in peptide binding. As indicated above, however, the antibody may inhibit peptide ligand-induced activation by other mechanisms, including cooperative effects with other regions of the receptor.
Cellular responses to a-thrombin have been extensively studied in a number of diverse model systems, with a suggestion, but no proof, ofthe presence of multiple receptors and/or signaling pathways (29, (35) (36) (37) . In fibroblasts (9) and vascular smooth muscle cells (37) , a-thrombin-induced mitogenic pathway(s) appear to be distinct from those associated with elevations of [Ca2+]i transients. Dual activation pathways and/ or coupling mechanisms have been described both in platelets (35, 38, 39) and in cultured human endothelial cells (3), possibly related to distinct G-proteins as determined by sensitivity to Bordetella pertussis toxin (38, 40) . Despite the recent identification of this TR, and the availability of activation peptide ligands and both polyclonal and monoclonal antibodies, the mechanism(s) of a-thrombin-mediated activation pathways are yet incompletely resolved (6, (34) (35) (36) (37) (38) (39) (40) . The data presented here are consistent with these previous observations of athrombin-mediated dual activation and/of receptor pathways. Whereas 30-- 
